List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Researchers have identified a protein that, when present in high amounts in breast cancer tumours, is an indicator of whether DNA-damaging therapies will work or not.
US researchers find that bacteria could help tumours progress and resist treatment.
US scientists have found strong evidence for testing VCU-manufactured drugs in liver cancer.
UPF and John Hopkins scientists have discovered how cancer cells exposed to high viscosity environments change their movements to improve their invasiveness and favour metastases.
Pre-clinical experiments involving cells from ICUs patients infected by SARS-CoV-2, and mice infected by MHV-A59 (murine hepatitis virus A59) show promise in treating COVID-19.
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
A new implant that combines internal radiation and chemotherapy dissolved tumours in mice across multiple models.
In pre-clinical studies, the University of Florida has identified two drugs that reverse ADM, a process that precedes pancreatic cancer.
The scientists found the mechanism of drug resistance depends on activation of a protein called KDM1B which controls and regulates gene expression.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
Deleting the gene POU2AF2 kills cancer cells in deadly subtype of small-cell lung cancer.
Researchers in Japan have succeeded in inhibiting cancer cell growth using pyrrolizidine alkaloid, a component of plant origin previously thought to be too toxic to administer.
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
